857 results on '"Kurosaki, M."'
Search Results
2. 73MO Regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Asia: Final analysis of the prospective, observational REFINE study
3. Early Surgery for Ruptured Aneurysms of the Posterior Circulation — 60 Consecutive Cases
4. Effects of HLA-DPB1 genotypes on chronic hepatitis B infection in Japanese individuals
5. A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)
6. The case for simplifying and using absolute targets for viral hepatitis elimination goals
7. The case for simplifying and using absolute targets for viral hepatitis elimination goals.
8. p38αMAPK interacts with and inhibits RARα: suppression of the kinase enhances the therapeutic activity of retinoids in acute myeloid leukemia cells
9. 975P The clinical impact of urinary protein creatinine ratio and AFP at six weeks in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
10. ITPA genetic variants influence efficacy of PEG-IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type
11. On a moving liquid film and its instability on textured surfaces
12. Noninvasive estimation of fibrosis progression overtime using the FIB-4 index in chronic hepatitis C
13. The Value of Intraoperative Cytology During Transsphenoidal Surgery for ACTH-Secreting Microadenoma
14. 1010P Real-world dosing of regorafenib (REG) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Interim analysis (IA) of the observational REFINE study
15. Abstract No. 616 Lusutrombopag is a safe treatment option for thrombocytopenia in patients with chronic liver disease undergoing a planned invasive procedure: pooled safety analysis from three studies
16. P461 Intolerance to 5-aminosalicylate is a risk of poor prognosis in ulcerative colitis patients
17. The natural history of untreated hepatocellular carcinoma
18. Selection of hepatitis C virus quasispecies during interferon treatment
19. Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin
20. Host dependent variation of hepatitis C virus: phylogenetic analyses
21. Variations in the core region of hepatitis C virus genomes in patients with chronic hepatitis
22. Expressional screening of interferon-stimulated genes for antiviral activity against hepatitis C virus replication
23. Site-specific mutation of the interferon sensitivity-determining region (ISDR) modulates hepatitis C virus replication
24. Characteristic sequence changes of hepatitis C virus genotype 2b associated with sustained biochemical response to IFN therapy
25. Introduction of NS5A mutations enables subgenomic HCV replicon derived from chimpanzee-infectious HC-J4 isolate to replicate efficiently in Huh-7 cells
26. Sequences in the NS5A protein of hepatitis C virus and the serum alanine aminotransferase response to interferon therapy in Japanese patients
27. The efficacy and safety of lenvatinib in patients who did not meet the inclusion criteria of the phase III trial (REFLECT trial) and those with BCLC Stage B hepatocellular carcinoma: A nationwide multicenter study in Japan
28. PF699 LUSUTROMBOPAG IS A SAFE TREATMENT OPTION FOR THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC LIVER DISEASE UNDERGOING A SCHEDULED INVASIVE PROCEDURE: POOLED SAFETY ANALYSIS FROM 3 STUDIES
29. Abstract P5-05-08: Molecular cross-talk between retinoic acid and NOTCH1 signaling pathways: Role in triple negative breast cancer
30. Abstract P2-02-15: All-trans retinoic acid perturbs the lipidomic profiles of luminal breast cancer cells characterized by sensitivity to the anti-proliferative activity of the retinoid
31. Abstract P5-05-09: Systemic perturbations induced by all-trans retinoic acid in the gene-expression profiles of sixteen breast cancer cell lines characterized by sensitivity and resistance to the anti-proliferative effects of the retinoid
32. Schwannoma originating in the optic canal
33. Usefulness of Ice Stick® in swallowing training
34. The effect of intensive physical therapy with repetitive transcranial magnetic stimulation in patients with degenerative cerebellar disease
35. Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts early occurrence of hepatocellular carcinoma in SVR achieved hepatitis C patients with interferon-free treatment
36. Comparison of the prognosis between non-viral HCC and viral HCC
37. Real world experience of lusutrombopag for thrombocytopenia in patients with liver cirrhosis
38. External validation of clinical scoring system for the prediction of hepatocellular carcinoma in chronic hepatitis B treated by nucleotide/nucleoside analogue
39. Hepatitis B surface antigen reduction by switching from long-term preceding nucleoside/nucleotide analog administration to pegylated interferon or tenofovir
40. Energy efficient industrial wireless system through cross layer optimization
41. A 1.2 Gbps Wireless LAN System for 4K Digital Cinema Transmission
42. Channel selectivity schemes for re-transmission diversity in industrial wireless system
43. A unified HW/SW system-level simulation framework for next generation wireless system
44. Re-transmission diversity with fast channel selectivity for reliable industrial WLAN system
45. Serum hepatocyte growth factor (HGF) is a potential marker for baseline liver function and its early deterioration in patients treated with sorafenib
46. Serum Wisteria Floribunda agglutinin-positive sialylated mucin 1 as a biomarker of hepatic progenitor cell/biliary features in hepatocellular carcinoma and of recurrence after curative therapy
47. Direct acting antivirals did not increase early recurrences after curative treatment of HCV related hepatocellular carcinoma in comparison with IFN-based treatment
48. 752P - The efficacy and safety of lenvatinib in patients who did not meet the inclusion criteria of the phase III trial (REFLECT trial) and those with BCLC Stage B hepatocellular carcinoma: A nationwide multicenter study in Japan
49. Unified HW/SW framework for efficient system level simulation
50. Design of WLAN based system for fast protocol factory automation system
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.